Mystery Patient Receives Eli Lilly’s New Obesity Drug Amidst Trump Speculation
The FDA’s Expanded Access program, intended for critically ill patients, recently facilitated access to an experimental drug for an unnamed individual. A senior clinician at the NIH requested the drug for a patient with refractory obesity and life-threatening pulmonary hypertension, a request that reportedly garnered significant attention from top health officials, suggesting the patient’s influential status. While the identity remains undisclosed, STAT has inquired with the White House regarding the possibility that the recipient is Donald Trump, who shares similar health concerns and a public interest in obesity medications.
John Q. Hosedrinker